Despite major advancements in the development of safer and more effective anticoagulant
agents, bleeding complications remain a significant concern in the treatment of …

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be
an effective and safe target for anticoagulant discovery with limited or no bleeding …

Thrombo-inflammation describes the complex interplay between blood coagulation and
inflammation that plays a critical role in cardiovascular diseases. The third Maastricht …

Objective—Factor XI (FXI) contributes to thrombotic disease while playing a limited role in
normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which …

Abstract Factor XIa (FXIa) is a serine protease homodimer that belongs to the intrinsic
coagulation pathway. FXIa primarily catalyzes factor IX activation to factor IXa, which …

Nonvalvular atrial fibrillation is a common rhythm disorder of middle-aged to older adults that
can cause ischemic strokes and systemic embolism. Lifelong use of oral anticoagulants …

Respiratory disease caused by a novel coronavirus, COVID-19, has been labeled a
pandemic by the World Health Organization. Very little is known about the infection …

Unique among coagulation factors, the coagulation factor XI (FXI) arose through a
duplication of the gene KLKB1, which encodes plasma prekallikrein. This evolutionary origin …

Atherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity.
Platelets and coagulation proteases, interacting with circulating cells and in different …

Introduction: Anticoagulation without bleeding is an ideal goal in treating thrombosis,
however, this goal has not been achieved. All current anticoagulants are associated with …